4.4 Review

Geriatric management of older patients with multimorbidity

期刊

GERIATRICS & GERONTOLOGY INTERNATIONAL
卷 20, 期 12, 页码 1105-1111

出版社

WILEY
DOI: 10.1111/ggi.14065

关键词

frailty; multimorbidity; polypharmacy

资金

  1. Astellas Pharma
  2. Bayer HealthCare
  3. Boehringer Ingelheim
  4. Chugai Pharmaceutical
  5. Daiichi Sankyo
  6. Eli Lilly Japan
  7. Eisai
  8. Kracie Pharma
  9. Mitsubishi-Tanabe Pharma
  10. MSD
  11. Novartis Japan
  12. Ono Pharmaceutical
  13. Sanofi
  14. Takeda Pharmaceutical
  15. Teijin Pharma
  16. Tsumura
  17. Health Labour Sciences Research Grant [H30-Ninchisho-Ippan-001]
  18. Japan Agency for Medical Research and Development [20ek0210107h0003]

向作者/读者索取更多资源

Older patients tend to have multimorbidity represented by multiple chronic diseases or geriatric conditions due to aging changes of organs, which require a variety of medical management. Currently, there are no sufficient disease treatment guidelines for older people with multimorbidity, therefore physicians have difficulty managing multimorbidity, such as which diseases should be treated intensively or to what extent the conditions should be improved. Furthermore, there are other points to be considered when initiating the treatment of diseases. For example, physicians must assess physical function. Some people have no difficulty with ambulation, but some are bedridden and have difficulty getting up on their own. As there are differences in disease severity, comorbid conditions and life expectancy, there should be differences in deciding treatment and prescribing drugs. It may be necessary to change the option for treatment depending on cognitive function, the living environment and the care environment, using comprehensive geriatric assessments. In addition, when treating multimorbidity, patients tend to have polypharmacy, which is a risk for adverse drug events. Because of this, it is necessary to consider dose reduction and drug discontinuation in patients with polypharmacy. Because of the global increase in older patients with multimorbidity, developing an essential method for managing multimorbidity is an urgent issue. More research and practices are necessary to achieve high-quality care in patients with multimorbidity.Geriatr Gerontol Int center dot center dot; center dot center dot: center dot center dot-center dot center dot Geriatr Gerontol Int 2020; center dot center dot: center dot center dot-center dot center dot.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据